Skip to main content

Table 4 Sensitivity and specificity of clinical and risk scores to identify individuals with subclinical atherosclerosisa

From: Subclinical atherosclerosis, cardiovascular health, and disease risk: is there a case for the Cardiovascular Health Index in the primary prevention population?

  Framingham Risk Scored Metabolic Syndromee Cardiovascular Health Indexf
  Intermediate Risk High Risk Yes Average Inadequate
Sensitivityb 33.9%
(33.8─33.9)
26.6%
(26.5─26.6)
36.7%
(36.6─36.7)
94.8%
(94.7─94.8)
78.0%
(77.8─78.1)
Specificityc 64.9%
(64.8─64.9)
87.4%
(87.3─87.4)
75.3%
(75.2─75.3)
14.9%
(14.8─14.9)
53.2%
(53.1─53.3)
  1. aProportion estimates of the eligible population after applying sampling weights to the study sample (% (95% CI))
  2. bSensitivity: probability of correctly detecting true positive results (individuals who do have subclinical atherosclerosis)
  3. cSpecificity: probability of correctly detecting true negative results (individuals who do not have subclinical atherosclerosis)
  4. dFramingham Risk Score: Intermediate (10–20% 10-year risk) or high risk (> 20% 10-year risk) vs. low risk (referent value; < 10% 10-year risk)
  5. eMetabolic syndrome: Presence of metabolic syndrome (3 or more risk factors) vs. no metabolic syndrome (referent value; < 3 risk factors)
  6. fCardiovascular Health Index (CVHI): Average CV health (5–9 total points) or inadequate CV health (0–4 total points) vs. optimum CV health (reference value; 10–14 total points)